Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
| Preferred Name | Erlotinib | |
| Synonyms |
|
|
| Definitions |
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C65530 |
|
| CAS_Registry |
183321-74-6
|
|
| CHEBI_ID |
CHEBI:114785
|
|
| Chemical_Formula |
C22H23N3O4
|
|
| code |
C65530
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.
|
|
| Display_Name |
Erlotinib
|
|
| FDA_UNII_Code |
J4T82NDH7E
|
|
| Has_Salt_Form | ||
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Erlotinib
|
|
| Legacy Concept Name |
Erlotinib_Base
|
|
| Maps_To |
Erlotinib
|
|
| Preferred_Name |
Erlotinib
|
|
| prefixIRI |
NCIT:C65530
|
|
| prefLabel |
Erlotinib
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C1135135
|
|
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping